

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Joji Nakayama, President and CEO  
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)  
Please address inquiries to Noriaki Ishida, Corporate Officer,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com/>

### **Daiichi Sankyo Selects Research Partners for TaNeDS Collaborative Drug Discovery Project**

**Tokyo, Japan (October 29, 2012)** — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has selected research partners for its TaNeDS (**T**ake a **N**ew challenge for **D**rug **d**iscovery) collaborative drug discovery project. The researchers were selected from universities and public research centers in Japan. Daiichi Sankyo will soon begin signing agreements with the selected parties to initiate collaborative research.

1. Total entries: 250

2. Selected parties: 20

3. Selections by entry type

	Entries	Those that passed second selection	Final selections
A. Theme/technology discovery	220	24	16
B. Theme/technology development	17	3	1
C. Pharmaceutical technology development	13	3	3
Total	250	30	20

4. Selections by research theme

	Entries	Those that passed second selection	Final selection
Oncology	103	7	4
Cardiovascular metabolics	71	8	3
Leading edge pharmaceuticals	58	3	3
Antibodies	41	8	5
Nucleic acid therapeutics, peptide pharmaceuticals, DDS	66	4	2
Pharmaceutical technology platforms	17	3	3
Total (Entries with multiple themes are counted once for each theme)	356	33	20

For more information about the TaNeDS program visit the Daiichi Sankyo corporate website:

<http://www.daiichisankyo.co.jp/rd/taneds/index.html> (Japanese only)